Sector News

Who’ll follow Sanofi CEO Olivier Brandicourt? The company’s eyeing candidates now

March 21, 2019
Life sciences

It’s been a tumultuous four years for Olivier Brandicourt at Sanofi, marked by restructuring, cost cuts, an asset swap and two M&A deals designed to upgrade the drugmaker’s rare disease business. What happens over the next four years is anybody’s guess, but the company’s working now to decide who’ll be at the helm, a spokeswoman said.

Sanofi is planning for Brandicourt’s departure because he’s two years away from his 65th birthday, and the company “sets the end of its CEO assignment at the age of 65,” the spokeswoman added.

“With this perspective, the board has been considering this succession plan for some time now, in agreement and consultation with our CEO,” Sanofi’s spokeswoman said.

Sources told Reuters that talks about the company’s future leadership have grown more intense in recent weeks. In February, Sanofi reported a sales decline for 2018, and just last week, the company disclosed it had cut Brandicourt’s pay by 25% to €7.28 million ($8.2 million), making his the smallest compensation package in Big Pharma.

Brandicourt has served as Sanofi’s CEO since April 2015, when he was brought in to lead the company after the board fired Chris Viehbacher, amid tensions over his leadership style. Brandicourt inherited a company facing intense pricing pressure in its key diabetes unit and a thin pipeline of new drug candidates.

Soon after taking the helm, he unveiled a restructuring plan to cut costs and jobs, focus on five business units and emphasize its rare disease group Genzyme.

He also started shopping for deals, with mixed results; the company lost out on Medivation in 2016 when Pfizer swooped in, and Actelion snubbed its takeover attempts before hooking up with Johnson & Johnson. But in 2016 Sanofi did ink an asset swap with Boehringer Ingelheim, sending away Sanofi’s animal health business in exchange for Boehringer’s consumer healthcare unit.

And in early 2018, Sanofi struck deals for Ablynx and Bioverativ in quick order, boosting its presence in rare blood diseases. Sanofi’s first med from the Ablynx deal, Cablivi, recently scored an FDA nod and carries peak sales estimates of $500 million.

Genzyme has delivered on a couple of other fronts, too. Dupixent, a Regeneron-partnered atopic dermatitis therapy approved in 2017, grew to €783 million ($887 million) last year. The drug has snagged new approvals in asthma and pediatric eczema patients, and it’s working on an indication in severe sinusitis. Kevzara, another Regeneron-partnered med, rolled out in 2017, with less success.

And one key launch under Brandicourt hasn’t panned out at all, at least not yet. The company’s dengue shot Dengvaxia, one of Viehbacher’s favorite projects, has been more of a liability than a sales engine as a safety controversy in the Philippines continues to generate negative headlines.

Sanofi isn’t the only drugmaker that’s had to contemplate replacing a retirement-age CEO over the past couple years. Last year, Merck & Co. changed its mandatory retirement rules to allow CEO Ken Frazier to stay in his post after he turns 65 this December.

And in 2017, Pfizer handed then-CEO Ian Read, who was eligible to retire at the time, an $8 million retention package to persuade him to stick around until March of this year; he bowed out as of Dec. 31, 2018, for new CEO Albert Bourla.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach